Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 165

1.

Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.

Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A.

Am J Hematol. 2009 Dec;84(12):790-4. doi: 10.1002/ajh.21561.

PMID:
19890907
[PubMed - indexed for MEDLINE]
2.

Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.

Pardanani A.

Am J Hematol. 2013 Jul;88(7):612-24. doi: 10.1002/ajh.23459. Epub 2013 May 30. Review.

PMID:
23720340
[PubMed - indexed for MEDLINE]
3.

Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.

Pardanani A.

Am J Hematol. 2011 Apr;86(4):362-71. doi: 10.1002/ajh.21982.

PMID:
21442641
[PubMed - indexed for MEDLINE]
4.

Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.

Pardanani A.

Am J Hematol. 2012 Apr;87(4):401-11. doi: 10.1002/ajh.23134. Review.

PMID:
22410759
[PubMed - indexed for MEDLINE]
5.

Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.

Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL.

Cancer. 2006 Jul 15;107(2):345-51.

PMID:
16779792
[PubMed - indexed for MEDLINE]
Free Article
6.

Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature.

Pardanani A, Tefferi A.

Curr Opin Hematol. 2010 Mar;17(2):125-32. doi: 10.1097/MOH.0b013e3283366c59. Review.

PMID:
20075725
[PubMed - indexed for MEDLINE]
7.

Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.

Yoshida C, Takeuchi M, Tsuchiyama J, Sadahira Y.

Intern Med. 2009;48(22):1973-8. Epub 2009 Nov 16.

PMID:
19915299
[PubMed - indexed for MEDLINE]
Free Article
8.

Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.

Sotlar K, Bache A, Stellmacher F, Bültmann B, Valent P, Horny HP.

J Mol Diagn. 2008 Jan;10(1):58-66. doi: 10.2353/jmoldx.2008.070061. Epub 2007 Dec 28. Erratum in: J Mol Diagn. 2009 May;10(3):276.

PMID:
18165278
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.

Florian S, Esterbauer H, Binder T, Müllauer L, Haas OA, Sperr WR, Sillaber C, Valent P.

Leuk Res. 2006 Sep;30(9):1201-5. Epub 2006 Jan 6.

PMID:
16406018
[PubMed - indexed for MEDLINE]
10.

On being metachromatic: mystique and misunderstanding in mastocytosis.

Gotlib J.

Am J Hematol. 2009 Dec;84(12):779-81. doi: 10.1002/ajh.21575. No abstract available.

PMID:
19899132
[PubMed - indexed for MEDLINE]
11.

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.

Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD.

Blood. 2004 Apr 15;103(8):3222-5. Epub 2003 Dec 24.

PMID:
15070706
[PubMed - indexed for MEDLINE]
Free Article
12.

In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.

Böhm A, Sonneck K, Gleixner KV, Schuch K, Pickl WF, Blatt K, Peter B, Herrmann H, Schernthaner GH, Pehamberger H, Rabitsch W, Sperr WR, Valent P.

Exp Hematol. 2010 Sep;38(9):744-55. doi: 10.1016/j.exphem.2010.05.006. Epub 2010 May 27.

PMID:
20553795
[PubMed - indexed for MEDLINE]
13.

Mastocytosis: state of the art.

Horny HP, Sotlar K, Valent P.

Pathobiology. 2007;74(2):121-32. Review.

PMID:
17587883
[PubMed - indexed for MEDLINE]
14.

Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).

Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bültmann B, Valent P, Horny HP.

J Pathol. 2010 Apr;220(5):586-95. doi: 10.1002/path.2677.

PMID:
20112369
[PubMed - indexed for MEDLINE]
15.

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.

Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Finke CM, Mullally A, Li CY, Pardanani A, Gilliland DG.

Leukemia. 2009 May;23(5):900-4. doi: 10.1038/leu.2009.37. Epub 2009 Mar 5.

PMID:
19262599
[PubMed - indexed for MEDLINE]
16.

[Systemic mastocytosis].

Fain O, Stirnemann J, Eclache V, Barete S, Casassus P, Hermine O, Lorholary O.

Presse Med. 2005 May 14;34(9):681-7. Review. French.

PMID:
15988348
[PubMed - indexed for MEDLINE]
17.

A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.

Mital A, Piskorz A, Lewandowski K, Wasąg B, Limon J, Hellmann A.

Eur J Haematol. 2011 Jun;86(6):531-5. doi: 10.1111/j.1600-0609.2011.01598.x. Epub 2011 Apr 7.

PMID:
21362052
[PubMed - indexed for MEDLINE]
18.

Systemic mastocytosis: current concepts and treatment advances.

Tefferi A, Pardanani A.

Curr Hematol Rep. 2004 May;3(3):197-202. Review.

PMID:
15087068
[PubMed - indexed for MEDLINE]
19.

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.

Ustun C, DeRemer DL, Akin C.

Leuk Res. 2011 Sep;35(9):1143-52. doi: 10.1016/j.leukres.2011.05.006. Epub 2011 Jun 8. Review.

PMID:
21641642
[PubMed - indexed for MEDLINE]
20.

Advanced mast cell disease: an Italian Hematological Multicenter experience.

Pagano L, Valentini CG, Caira M, Rondoni M, Van Lint MT, Candoni A, Allione B, Cattaneo C, Marbello L, Caramatti C, Pogliani EM, Iannitto E, Giona F, Ferrara F, Invernizzi R, Fanci R, Lunghi M, Fianchi L, Sanpaolo G, Stefani PM, Pulsoni A, Martinelli G, Leone G, Musto P.

Int J Hematol. 2008 Dec;88(5):483-8. doi: 10.1007/s12185-008-0166-4. Epub 2008 Nov 26.

PMID:
19034614
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk